SCHEMBL905453

SCHEMBL905453

CCCC[C@@H](C)CC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.52
ACE2 Q9BYF1 1/20 0.50
CA2 P00918 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 1/20 0.44
BHMT Q93088 1/20 0.44
AKR1B1 P15121 1/20 0.42
PPARG P37231 4/20 0.41
PPARD Q03181 4/20 0.41
PPARA Q07869 4/20 0.41
TSHR P16473 3/20 0.41
HDAC11 Q96DB2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
TLR2 O60603 1/20 0.41
MEN1 O00255 1/20 0.41
ESR1 P03372 1/20 0.41
FABP4 P15090 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL301256 1.00 GPR84 (0.52) GPR84ACE2CA2MAPK1MAPT
SCHEMBL4435960 1.00 GPR84 (0.52) GPR84ACE2CA2MAPK1MAPT
Hydrochloric Acid SCHEMBL27778084 0.98 GPR84 (0.50) GPR84ACE2CA2MAPK1MAPT
SCHEMBL28055317 0.98 GPR84 (0.50) GPR84ACE2CA2MAPK1MAPT
SCHEMBL5858405 0.94 ACE2 (0.60) GPR84ACE2CA2MAPK1MAPT
SCHEMBL544052 0.93 GPR84 (0.61) GPR84ACE2MAPTAKR1B1PPARG
SCHEMBL30882121 0.93 GPR84 (0.61) GPR84ACE2MAPTAKR1B1PPARG
SCHEMBL23930717 0.91 GPR84 (0.64) GPR84ACE2MAPTPPARGPPARD
SCHEMBL17772493 0.91 GPR84 (0.64) GPR84ACE2MAPTPPARGPPARD
SCHEMBL22612526 0.91 GPR84 (0.64) GPR84ACE2MAPTPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118894772-A Preparation method of key intermediate of high optical purity limaprost 常州博海威医药科技股份有限公司 2024-11-05 CN claimed
US-20080233621-A1 Method For Producing Alcohol and Carboxylic Acid Having Optical Activity API CORPORATION (JP) 2008-09-25 US claimed
EP-1712630-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL AND CARBOXYLIC ACID API Corporation (JP) 2006-10-18 EP claimed
CN-121471055-A Method for synthesizing (R) -3-methylheptanoic acid 临沂大学 2026-02-06 CN disclosed
CN-121471055-A Method for synthesizing (R) -3-methylheptanoic acid 临沂大学 2026-02-06 CN disclosed
WO-2025096734-A1 MICROCAPSULES FMC CORPORATION (US) 2025-05-08 WO disclosed
CN-118894772-A Preparation method of key intermediate of high optical purity limaprost 常州博海威医药科技股份有限公司 2024-11-05 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2716642-B1 IMIDAZOPYRIDINE COMPOUND ASTELLAS PHARMA INC (JP) 2016-07-20 EP disclosed
EP-2278014-A2 Method for producing alcohol and carboxylic acid having optical activity API Corporation (JP) 2011-01-26 EP disclosed
EP-2270178-A2 Method for producing alcohol and carboxylic acid having optical activity API Corporation (JP) 2011-01-05 EP disclosed
EP-1748975-B1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 3-ALKYL CARBOXYLIC ACIDS AND THE INTERMEDIATE PRODUCTS THEREOF WACKER CHEMIE AG (DE) 2008-02-13 EP disclosed
US-20070225519-A1 Method for the Production of Optically Active 3-Alkyl Carboxylic Acids and the Intermediate Products Thereof CONSORTIUM FUER ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 2007-09-27 US disclosed
CN-101027278-A Preparation of beta-amino acids having affinity for the alpha-2-delta protein WARNER LAMBERT CO (US) 2007-08-29 CN disclosed
EP-1768952-A2 PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN Warner-Lambert Company LLC (US) 2007-04-04 EP disclosed
EP-1748975-A1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 3-ALKYL CARBOXYLIC ACIDS AND THE INTERMEDIATE PRODUCTS THEREOF Consortium für elektrochemische Industrie GmbH (DE) 2007-02-07 EP disclosed
EP-1712630-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL AND CARBOXYLIC ACID API Corporation (JP) 2006-10-18 EP disclosed
WO-2006008612-A2 PREPARATION OF BETA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2006-01-26 WO disclosed
WO-2005115955-A1 METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE 3-ALKYL CARBOXYLIC ACIDS AND THE INTERMEDIATE PRODUCTS THEREOF Consortium für elektrochemische Industrie GmbH (DE) 2005-12-08 WO disclosed
US-6093345-A PYRIMIDINE COMPOUNDS, ELECTROOPTICS TAKASAGO INTERNATIONAL CORPORATION (JP) 2000-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225519-A1 Method for the Production of Optically Active 3-Alkyl Carboxylic Acids and the Intermediate Products Thereof ME1, ME3, ACMSD GPR84 1331/4885ACE2 1773/4885CA2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.